


GSK eyes emerging markets with \$27 mn investment

21 November 2014 | News | By BioSpectrum Bureau

GSK eyes emerging markets



Singapore: Recently GlaxoSmithKline has announced introduction of a new technology to its Boronia manufacturing site in Australia, designed to meet the growing demand of emerging markets. The company said that it will be investing \$27 million for the entire project.

GSK spokesperson said in a statement that the plant will see a new high-speed blow-fill-seal machine dedicated for the manufacturing of Ventolin (salbutamol sulfate) nebulas, or doses inhaled through a nebulizer. The new machine will increase the plant's manufacturing capacity by 100 million nebulas annually.

The increase in production will help in providing low-cost asthma treatments to the needy people in emerging markets. The new machine is expected to start production from January 2016. Boronia is the GSK's largest site worldwide for the production of sterile and non-sterile liquid products.

Over the years, the Boronia site has been the drug giant's major focus both for investment and expansion. GSK had spent \$52 million in 2012 to double the capacity of the Boronia site through a new Blow-Fill-Seal machinery, a project that was planned to create 58 new jobs by 2017.